📰 Nuclear Export News
Page 6 - Nuclear Export News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nuclear Export. Real-time updates on events, politics, business and more.
July 17, 2023
KPTI | Complete Karyopharm Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
July 17, 2023
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...
July 7, 2023
Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Free Report) crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $3.05 and traded as low as $1.64. Karyopharm Therapeutics shares last traded at $1.65, with a volume of 2,684,629 shares. Analysts Set New […]
July 5, 2023
NEWTON, Mass., July 5, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an...
July 5, 2023
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...
July 1, 2023
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Free Report) has been assigned an average recommendation of “Moderate Buy” from the seven analysts that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among […]
June 26, 2023
Karyopharm Therapeutics (NASDAQ:KPTI – Get Rating) and Alimera Sciences (NASDAQ:ALIM – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability. Valuation and Earnings This table compares Karyopharm Therapeutics and […]
June 6, 2023
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) has been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are currently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month target […]
June 1, 2023
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...
June 1, 2023
NEWTON, Mass., June 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an... | June 1, 2023